

## Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

by Pierre Peterlin and Maxime Jullien

Received: January 13, 2025.

Accepted: January 20, 2025.

Citation: Pierre Peterlin and Maxime Jullien. Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Haematologica. 2025 Jan 30. doi: 10.3324/haematol.2025.287378 [Epub ahead of print]

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.*

*E-publishing of this PDF file has been approved by the authors.*

*After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.*

*All legal disclaimers that apply to the journal also pertain to this production process.*

**Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies**

Pierre Peterlin,<sup>1</sup> Maxime Jullien<sup>1</sup>

<sup>1</sup> Clinical Hematology, Nantes University Hospital, Nantes, France

Correspondence:

Dr Pierre Peterlin  
Service d'Hématologie Clinique  
CHU Hôtel-Dieu  
Place A. Ricordeau  
44093 Nantes Cedex  
France.  
Phone: (33) 240083271  
[pierre.peterlin@chu-nantes.fr](mailto:pierre.peterlin@chu-nantes.fr)

***Dear Editor,***

We thank Yan and Liu for their comment regarding the multivariate analysis in our study<sup>1</sup>.

We acknowledge that this analysis does not entirely comply with the 10 events-per-variable (EBV) rule, a rule of thumb that is commonly used to guide model complexity in small datasets<sup>2</sup>.

While we recognize the limitations of our analysis due to the small sample size of 28 patients, we limited our model to 4 covariables (not 7 as suggested), and used Firth's bias-reduced logistic regression to address the small sample size<sup>3</sup>. sFL kinetics was identified as significant in univariate analysis, and we considered relevant to evaluate whether this positive effect persisted when taking into account covariables that are classically associated with prognosis in MDS.

It is important to note that this study is exploratory in nature, and as such aims to identify trends and generate hypotheses, rather than draw definitive conclusions. Despite these limitations, our results suggest that the sFL profile may be an interesting marker in high-risk MDS and CMML, and deserves further investigation in larger, adequately powered cohorts.

**References:**

- 1 - Peterlin P, Gaschet J, Turlure P, et al. FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. *Haematologica*. 2024 Nov 21. [Epub ahead of print]
- 2 - Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. *BMJ*. 2015;351:h3868.
- 3 - Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Stat Med*. 2002;21(16):2409-2419.